CellRep Company Profile, Contacts & Intelligence

Biotechnology ResearchThe Critical Limitations in Today's Car-t Therapies: Poor Efficacy in Solid Tumors6 employeesFounded 2024
1 contact with email or phone data1 with email data
View verified contacts Compare competitors
Employees
6
Company source estimate
Reachable Contacts
1
Visible contacts with email or phone data
Contacts With Email
1
1 of 3 visible contacts

CellRep Overview

Dynamic cell reprogramming without gene editing making personalized medicine scalable. We're starting with cancer and soon extending longevity. CellRep is revolutionizing cell therapy based on our co-founder Dr. Federico Perdomo's groundbreaking discovery that cells are programmable biological supercomputers. While at Institut Pasteur, Dr. Perdomo demonstrated that dysfunctional T cells could be reprogrammed with small molecules to emulate the extraordinary properties of T cells from HIV natural controllers—creating rejuvenated fighters with enhanced survival, polyfunctionality, and metabolic plasticity. Our AI-powered platform expands on this breakthrough through our integrated In Silico, In Vitro, and In Vivo approach, dynamically reprogramming T cells without genetic modification to address the critical limitations in today's CAR-T therapies: poor efficacy in solid tumors, lengthy manufacturing times, and prohibitive costs. We've already identified 15+ novel molecular targets and achieved a 2.5x improvement in T cell functionality—47% better than Dr. Perdomo's original breakthrough. Our technology produces more polyfunctional, "younger" T cells with potential to reduce manufacturing time by 45% while improving therapeutic outcomes by 50%. With strategic partnerships established with major research institutions and engagement from leading pharmaceutical companies, we're transforming the $7B CAR-T market (projected to reach $188B by 2034) while building the definitive bio-compiler for cellular medicine across multiple therapeutic areas.

Headquarters
The Critical Limitations in Today's Car-t Therapies: Poor Efficacy in Solid Tumors
Website
cellrep.bio
Industry
Biotechnology Research
Founded
2024
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
Immunology Bioinformatics Biochemistry Artificial Intelligence GenAI Drug Discovery

CellRep Contact Intelligence

See which contact channels and departments are represented in the visible AeroLeads data.

1 contact with contact data
1 with email data in the visible sample.

CellRep People & Org Chart Preview

Sample people records show job titles and whether email or phone data is available without exposing raw contact details.

M
Manuel Franco
Cco and Cofounder Cellrep
F
Fabiola Martel
Microbióloga Con Orientación En Análisis Clínico; Msc; Esp. Phd Student Biological Sciences - Immunology
J
Julian Ganzabal
Caio & Co-founder @ Cellrep Bio
E

CellRep Workforce Composition

Seniority breakdown across 3 visible profiles.

Individual contributor
2
Executive
1

Compare Similar Companies to CellRep

Explore companies in related markets and compare their industry and employee estimates.

Company Industry / match Employee estimate Page
GRIDX Venture Capital And Private Equity Principals 20 View company
Bioplastix Biotechnology Research 8 View company
CyanoMin Biotechnology Research 7 View company
BioBlends Biotechnology Research 6 View company
MIGMA Food And Beverage Services 5 View company
POLYMERA Biotechnology Research 5 View company
APASOMICS Biotechnology Research 3 View company
Biodiversity Intelligence Biotechnology Research 3 View company
Invitrall Biotechnology Research 3 View company
MicroIN Biotechnology Research 2 View company